HLS
DEAD

Serial Number

86925652

Owner

HLS Therapeutics Inc.

Attorney

Megan K. Bowen

Filing Date

Mar 2, 2016

Add to watchlist:

No watchlists yet
View on USPTO

HLS Trademark

Serial Number: 86925652 • Registration: 5796691

HLS is a trademark filed by HLS Therapeutics Inc. on March 2, 2016. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

HLS Therapeutics Inc. (5 trademarks)

10 Carlson Court, Suite 410
Toronto M9W6L2 , CA

Entity Type: 03

Trademark Details

Filing Date

March 2, 2016

Registration Date

July 9, 2019

Published for Opposition

August 21, 2018

Cancellation Date

January 23, 2026

Goods & Services

Pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes, cardiovascular disorders, central nervous system (CNS) disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy, neurological disorders, namely, brain injury, spinal cord injury, seizure disorders, dermatological disorders, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases, respiratory, gastrointestinal and other metabolic disorders, namely, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism, osteoporosis and other bone disorders, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, immunomodulatory diseases, namely, autoimmune diseases, immunologic deficiency syndromes; and antidepressants, antivirals, antibacterial pharmaceuticals, antifungal preparations, anti-inflammatories, analgesics and other pain therapeutics, namely, pain relief medications in the nature of muscle relaxants, anti-anxiety and anti-convulsion medications and acetaminophen, pharmaceutical preparations to treat diseases of the genitourinary system in women, hormones, namely, progesterone, progestins, and estrogens, hormone receptor modulators, and osteoporosis medicines

Pharmaceutical drug formulation development; clinical evaluation and testing in the nature of conducting clinical trials relating to pharmaceuticals

Filing History

CANCELLED SEC. 8 (6-YR)
Jan 23, 2026 C8..
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Sep 10, 2025 ASCK
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 9, 2024 REM1
REGISTERED-PRINCIPAL REGISTER
Jul 9, 2019 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Jun 4, 2019 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 4, 2019 AITU
NOTICE OF ALLOWANCE CANCELLED
May 20, 2019 IUCN
TEAS POST PUBLICATION AMENDMENT RECEIVED
May 20, 2019 EPPA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 13, 2019 EXRA
SOU EXTENSION 1 GRANTED
Apr 11, 2019 EX1G
SOU EXTENSION 1 FILED
Apr 11, 2019 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 11, 2019 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 16, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 21, 2018 NPUB
PUBLISHED FOR OPPOSITION
Aug 21, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 1, 2018 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Jul 17, 2018 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Jul 13, 2018 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 9, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 9, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 9, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 9, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 9, 2018 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 11, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jan 11, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jan 11, 2018 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 22, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 22, 2017 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 15, 2017 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jul 21, 2017 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jul 21, 2017 GNSI
SUSPENSION INQUIRY WRITTEN
Jul 21, 2017 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 20, 2017 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 19, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 19, 2017 GNSL
SUSPENSION LETTER WRITTEN
Jan 19, 2017 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 19, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 19, 2017 CRFA
ASSIGNED TO LIE
Jan 13, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 15, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 17, 2016 GNRN
NON-FINAL ACTION E-MAILED
Jun 17, 2016 GNRT
NON-FINAL ACTION WRITTEN
Jun 17, 2016 CNRT
ASSIGNED TO EXAMINER
Jun 16, 2016 DOCK
ASSIGNED TO EXAMINER
Jun 15, 2016 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Mar 8, 2016 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 7, 2016 NWOS
NEW APPLICATION ENTERED
Mar 5, 2016 NWAP